Article
Pharmacokinetic recall study of Estonian Biobank participants carrying novel genetic variants in CYP2C19 and CYP2D6
2025-07-15
Abstract excerpt
<title>Abstract</title> <p><bold>Background</bold>: <italic>CYP2C19</italic> and <italic>CYP2D6</italic> collectively account for the hepatic metabolism of approximately 35–40% of clinically used drugs. Their genetic polymorphisms significantly influence drug response, including the risk of adverse drug reactions. However, the genetic basis for interindividual differences remains incompletely understood, with mis...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 37619ddf-25db-52ca-9819-61f2deaf3eb5
- DOI
- 10.21203/rs.3.rs-7084648/v1
